QC
DNA icon

Quadrature Capital’s Ginkgo Bioworks DNA Stock Holding History

Quadrature Capital’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$457K Buy
+46,088
New +$385K ﹤0.01% 1036
2023
Q2 		– Sell
-516
Closed -$27.4K – 1037
2023
Q1 		$27.4K Buy
+516
New +$32.7K ﹤0.01% 875

Other funds holding DNA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JMFC
J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Quadrature Capital's DNA Position: Q2 2026 in Review

Quadrature Capital opened a new position in Ginkgo Bioworks (DNA) in Q2 2026: 46,088 shares worth $457K. The stake represents ﹤0.01% of the portfolio and ranks #1036 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in DNA as recently as Q1 2023.

Quadrature Capital first reported a position in DNA in Q1 2023 and has held it in 2 quarters since. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

  • Quadrature Capital held 46,088 shares of Ginkgo Bioworks worth $457K as of Q2 2026.
  • Ginkgo Bioworks was a new Quadrature Capital position in Q2 2026.
  • Ginkgo Bioworks made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1036 holding.
  • Quadrature Capital first reported a position in Ginkgo Bioworks in Q1 2023 and has held it in 2 quarters since.
  • 184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.